Otonomy, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.6M
Doctors Paid
395
Transactions
1,758
2021 Total
$123,263
Payment Breakdown by Category
Research$10.7M (92.9%)
Consulting$477,801 (4.1%)
Food & Beverage$13,314 (0.1%)
Royalty/License$12,987 (0.1%)
Travel$10,882 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.7M | 1,008 | 92.9% |
| Consulting Fee | $477,801 | 117 | 4.1% |
| Grant | $200,671 | 3 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,527 | 61 | 0.9% |
| Food and Beverage | $13,314 | 420 | 0.1% |
| Royalty or License | $12,987 | 17 | 0.1% |
| Travel and Lodging | $10,882 | 25 | 0.1% |
| Education | $1,919 | 106 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
Payments by Type
Research
$10.7M
1,008 transactions
General
$824,601
750 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $6.0M | 11 | 178 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus | $2.3M | 1 | 110 |
| STUDY OF OTO-104 IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE | $842,639 | 2 | 283 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERE'S DISEASE | $538,440 | 1 | 238 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single intratymoanic injection in subjects with speech-in-noise hearing impairment | $351,801 | 0 | 23 |
| STUDY OF OTO-104 IN SUBJECTS AT RISK FROM CISPLATIN-INDUCED HEARING LOSS | $318,156 | 10 | 62 |
| PHASE 3 STUDY OF OTO-201 IN ACUTE OTITIS EXTERNA | $175,057 | 4 | 70 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single Intratympanic injection in subjects with speech-in-noise hearing impairment | $119,163 | 0 | 11 |
| OPEN-LABEL STUDY OF OTO-201 IN PEDIATRIC SUBJECTS WITH A HISTORY OF OTITIS MEDIA REQUIRING TYMPANOSTOMY TUBES | $71,042 | 1 | 22 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment | $15,492 | 0 | 1 |
| A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $10,500 | 0 | 4 |
| A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safetystudy of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease. | $5,450 | 0 | 2 |
| A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $4,004 | 0 | 1 |
| An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes | $1,138 | 0 | 1 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERES DISEASE | $80.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 12
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. Han-Soo Bae, M.d, M.D | Otolaryngology | Monroe, MI | $15.53 | $0 |
| Dr. Andrew Karpenko, Md, MD | Otolaryngology | Monroe, MI | $15.53 | $0 |
| Dr. Benjamin Murcek, D.o, D.O | Otolaryngology | Sandusky, OH | $15.49 | $0 |
| Dr. Paul Biedenbach, D.o, D.O | Otolaryngology | Clyde, OH | $15.49 | $0 |
| David Parry, M.d, M.D | Allergy | Pocatello, ID | $15.43 | $0 |
| Christopher Dehan | Otolaryngology | Austin, TX | $15.43 | $0 |
| Arthur Morgan, M.d, M.D | Otolaryngology | Austin, TX | $15.43 | $0 |
| Bradford Winegar | Otolaryngology | Austin, TX | $15.43 | $0 |
| N Heindel, M.d, M.D | Otolaryngology | Newnan, GA | $15.39 | $0 |
| Syboney Zapata, Md, MD | Pediatric Otolaryngology | Corpus Christi, TX | $15.38 | $0 |
| Corrie Roehm, Md, MD | Otolaryngology | Austin, TX | $15.38 | $0 |
| Dr. Jared Wasserman, M.d, M.D | Otolaryngology | Hackensack, NJ | $15.37 | $0 |
| Dr. John Ansley, Md, MD | Otolaryngology | Orangeburg, SC | $15.31 | $0 |
| Dr. Erin Pierce, M.d, M.D | Pediatrics | Norfolk, NE | $15.20 | $0 |
| Dr. Joseph Sciarrino, M.d, M.D | Otolaryngology | Cumming, GA | $15.20 | $0 |
| Dr. Daniel Blomenberg | Pediatrics | Norfolk, NE | $15.20 | $0 |
| Dr. Renato Giacchi, Md, MD | Otolaryngology | Morristown, NJ | $15.16 | $0 |
| Javan Nation, M.d, M.D | Otolaryngology | Orlando, FL | $15.15 | $0 |
| Shelby Leuin, Md, MD | Otolaryngology | San Diego, CA | $15.15 | $0 |
| Anthony Magit, M.d, M.D | Otolaryngology | San Diego, CA | $15.15 | $0 |
| Dr. Yu-Lan Mary Ying, M.d, M.D | Otology & Neurotology | Newark, NJ | $15.09 | $0 |
| James Gordon, M.d, M.D | Otolaryngology | Tucson, AZ | $15.09 | $0 |
| Rowley Busino, Md, MD | Otolaryngology | La Mesa, CA | $15.09 | $0 |
| Dr. Robert Defatta, Md, Ph D, Facs, MD, PH D, FACS | Otolaryngology | Altoona, WI | $15.09 | $0 |
| Mr. Majid Torabi, M.d, M.D | Otolaryngic Allergy | Rancho Mirage, CA | $14.80 | $0 |
About Otonomy, Inc.
Otonomy, Inc. has made $11.6M in payments to 395 healthcare providers, recorded across 1,758 transactions in the CMS Open Payments database. In 2021, the company paid $123,263. The top product by payment volume is OTO-313 ($513,049).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Internal Medicine ($339,126 to 5 doctors).
Payment categories include: Food & Beverage ($13,314), Consulting ($477,801), Research ($10.7M), Travel & Lodging ($10,882), Royalties ($12,987).
Otonomy, Inc. is associated with 4 products in the CMS Open Payments database, including OTO-313, OTO-413, and OTO-104.